NCT00186979已完成1 期
A Phase I Study of ZD1839 (Iressa) in Combination With Irinotecan (Camptosar or CPT-11) and Vincristine in Pediatric Patients With Refractory Solid Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 34
- 试验地点
- 1
- 主要终点
- Dose limiting toxicities
研究概览
简要总结
The purpose of this protocol is to estimate the maximum tolerated dose of gefitinib in combination with fixed dose of irinotecan and vincristine in patients with refractory solid tumors.
详细描述
Objectives of this study are:
- To determine the dose-limiting toxicities (DLT) of the combination of irinotecan and ZD1839 when given on this schedule.
- To characterize the pharmacokinetics and pharmacodynamics of gefitinib alone and in combination with irinotecan and vincristine.
- To estimate the maximum tolerated dose (MTD) of gefitinib in combination with escalating intravenous irinotecan by using selective intestinal decontamination with oral cefixime or cefpodoxime to prevent diarrhea.
- To estimate the MTD of vincristine (MTD) in combination with gefitinib and irinotecan.
Details of Treatment Interventions
First Cohort:
Standard dose escalation, starting at ZD1839 150 mg/m2/day for 21 days in combination with irinotecan 15mg/m2/day on a daily x 5 for two consecutive week schedule. Dose-limiting diarrhea was seen in this cohort. ZD scheduled was reduced to 12 days. The first dose level (1a) consisted of ZD1839 112.5mg/m2/day for 12 days + irinotecan 15mg/m2/day daily x 5 x 2 and was found to be the MTD in this cohort.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- — 至 21 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Younger than 22 years of age.
- •Histologic verification of solid tumor malignancy at original diagnosis.
- •Has disease considered refractory to conventional therapy or no conventional therapy exists.
- •Adequate performance status, bone marrow, liver and kidney function.
- •Patients must not have had any previous allergic reactions to penicillin or cephalosporins
排除标准
- •Known severe hypersensitivity to ZD1839 or any of the excipients of this product
- •Concomitant use of phenytoin, carbamazepine, barbiturates, rifampicin, phenobarbital, or St John's Wort, and CYP3A4 inhibitors
- •Treatment with a non-approved or investigational drug within 30 days before Day 1 of trial treatment.
- •Incomplete healing from previous oncologic or other major surgery
- •Pregnant or breast-feeding
- •Patients who have an uncontrolled infection
- •Any evidence of clinically active interstitial lung disease (patients with chronic stable radiographic changes who are asymptomatic need not be excluded).
- •As judged by the investigator, any evidence of uncontrolled systemic disease (e.g., unstable or uncompensated respiratory, cardiac, hepatic, or renal disease).
- •Evidence of any other significant clinical disorder or laboratory finding that makes is undesirable for the subject to participate in the trial.
研究组 & 干预措施
1
Other
干预措施: Irinotecan, ZD1839, Vincristine, Cefixime, Cefpodoxime. (Drug)
结局指标
主要结局
Dose limiting toxicities
时间窗: Within the first 30 days of completion of first cycle
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
终止
1 期
Gefitinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III or Stage IV Head and Neck CancerStage III Squamous Cell Carcinoma of the HypopharynxStage III Squamous Cell Carcinoma of the LarynxStage III Squamous Cell Carcinoma of the Lip and Oral CavityStage III Squamous Cell Carcinoma of the OropharynxStage IV Squamous Cell Carcinoma of the HypopharynxStage IV Squamous Cell Carcinoma of the LarynxStage IV Squamous Cell Carcinoma of the Lip and Oral CavityStage IV Squamous Cell Carcinoma of the OropharynxNCT00033449National Cancer Institute (NCI)30
已完成
1 期
ZD1839 (Iressa™) and Concurrent Chemo-Radiation in Patients With Locally Advanced Non Small Cell Lung CancerNon Small Cell Lung CarcinomaNCT00252798AstraZeneca44
已完成
1 期
IRESSA Combined With Radiotherapy & Gemcitabine as First-Line Treatment in Locally Advanced Pancreatic CancerPancreatic CancerNCT00234416AstraZeneca45
已完成
1 期
Gefitinib (Iressa) in Combo With Chemoradiation in Patients With Locally Advanced Head & Neck CancerHead and Neck NeoplasmsNCT00239304AstraZeneca40
已完成
1 期
ZD 1839 Plus Combination Chemotherapy in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Colorectal CancerColorectal CancerNCT00026364National Cancer Institute (NCI)22